Gmitrov J, Andrejko S
Department of Physiological Hygiene, National Institute of Public Health, Tokyo, Japan.
Wien Klin Wochenschr. 2000 Feb 25;112(4):162-8.
Epidemiological evidence indicates that depressed baroreflex sensitivity and heart rate variability are associated with reduced survival secondary to coronary heart disease as well as with an increased risk of developing coronary heart disease. In view of the conflicting data in the literature concerning the effect of calcium channel antagonists on autonomic balance, we evaluated the effect of verapamil on heart rate and blood pressure variability, and on baroreflex sensitivity.
Baroreflex sensitivity was studied in 11 rabbits (27 series) under slight sedation induced by pentobarbital infusion (5 mg/kg/hour), both with a steady-state method using phenylephrine-induced blood pressure ramps, and by spectral analysis estimating the transfer function from mean arterial blood pressure to heart rate. Mean arterial blood pressure in the femoral artery, heart rate, and a microphotoelectric plethysmogram of the capillary network of rabbit's ears were simultaneously recorded during the entire experiment. Baroreflex sensitivity was measured before and after 30 min of verapamil infusion (20 micrograms/kg/min).
Verapamil-reduced baroreflex sensitivity measured by steady-state (2.6 +/- 0.2-1.7 +/- 0.2 beats/min/mmHg, mean +/- SEM) and transfer function methods (19.0 +/- 3.1-5.3 +/- 0.9; control vs. verapamil infusion, p < 0.001), and increased cardiovascular variability as estimated both by standard deviation in mean arterial blood pressure (2.0 +/- 0.1-4.0 +/- 0.4 mm Hg) and standard deviation in heart rate (6.5 +/- 1.0-9.8 +/- 1.1 bpm; p < 0.05). Verapamil increased heart rate (+3%; p < 0.05), reduced systemic mean arterial blood pressure (-12%; p < 0.05), and mean arterial blood pressure swings induced by increasing doses of phenylephrine bolus injections (-6% to -15%; p < 0.05). The reduction was larger for larger blood pressure ramps and exceeded the systemic arterial pressure reduction induced by verapamil infusion. A nonsignificant trend towards an increase in microcirculation was observed.
Besides the direct cardiodepressant and vasodilatatory action of verapamil, its suppressive effect on baroreflex sensitivity should be taken into account, since this sensitivity might contribute to an increased risk of cardiac morbidity and mortality.
流行病学证据表明,压力反射敏感性降低和心率变异性与冠心病继发的生存率降低以及患冠心病风险增加有关。鉴于文献中关于钙通道拮抗剂对自主神经平衡影响的数据相互矛盾,我们评估了维拉帕米对心率和血压变异性以及压力反射敏感性的影响。
在戊巴比妥输注(5毫克/千克/小时)诱导的轻度镇静下,对11只兔子(27个系列)进行压力反射敏感性研究,采用苯肾上腺素诱导的血压斜坡稳态法以及通过估计从平均动脉血压到心率的传递函数的频谱分析。在整个实验过程中,同时记录股动脉平均动脉血压、心率以及兔耳毛细血管网络的微光电体积描记图。在输注维拉帕米(20微克/千克/分钟)30分钟前后测量压力反射敏感性。
通过稳态法(2.6±0.2 - 1.7±0.2次/分钟/毫米汞柱,平均值±标准误)和传递函数法(19.0±3.1 - 5.3±0.9;对照与维拉帕米输注,p < 0.001)测量,维拉帕米降低了压力反射敏感性,并增加了心血管变异性,这通过平均动脉血压标准差(2.0±0.1 - 4.0±0.4毫米汞柱)和心率标准差(6.5±1.0 - 9.8±1.1次/分钟;p < 0.05)来估计。维拉帕米使心率增加(+3%;p < 0.05),降低了全身平均动脉血压(-12%;p < 0.05),以及由递增剂量苯肾上腺素推注引起的平均动脉血压波动(-6%至-15%;p < 0.05)。血压斜坡越大,降低幅度越大,且超过了维拉帕米输注引起的全身动脉压降低幅度。观察到微循环有不显著的增加趋势。
除了维拉帕米的直接心脏抑制和血管舒张作用外,还应考虑其对压力反射敏感性的抑制作用,因为这种敏感性可能会增加心脏发病和死亡风险。